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The presence of metastatic lymph nodes is one of the 
major adverse prognostic factors in many cancers, 
including endometrial adenocarcinoma (EC). In EC, the 
vast majority of nodal involvement is microscopic, 
which cannot be accurately diagnosed by non-surgical 
means. This fact is reflected by the introduction of 
surgical staging including systematic lymphadenectomy 
in EC by FIGO. Diagnostic lymph node sampling is 
inherently inaccurate in evaluating the nodal status 
and the feasibility of the sentinel node concept in 
EC has not been proven. Currently, there is no 
alternative to adequate lymph node dissection in 
identifying lymphatic involvement. As paraaortic 
nodal metastasis may occur in the absence of pelvic 
node involvement in EC, there is general consensus 
that paraaortic node dissection is required for 
adequate systematic lymphadenectomy.   
 
However, lymph node dissection may not be easy in 
some patients who are at high operative risk due to 
age and associated medical conditions such 
arteriosclerosis, hypertension, diabetes, poor 
general condition, etc. Albeit serious intra- and 
postoperative complications may occur, significantly 
increased complication rates have not been reported 
and pelvic-paraaortic lymphadenectomy is a safe 
procedure in skilled hands.    
 
One of the major concerns of routine node dissection 
in EC includes the fact that the majority of women 
with clinically early-stage EC do not have nodal 
involvement and their survival rates are excellent 
without lymph node dissection. Node dissection in 
this cohort of EC is overtreatment, has no benefit 
but increases the risk of surgical complications. 
 
Currently, the indication for node dissection in 
seemingly uterine-confined EC has been based on the 
depth of myometrial invasion (substage) and the grade 
of the tumour. The frequency of lymph node 
involvement is well in accordance with these 
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prognostic variables: more than 95% of superficially 
invasive, well differentiated (grade 1) EC is 
pathologically confined to the uterus, whereas, over 
60% of patients with stage I, deeply invaded, grade 3 
tumours have extrauterine disease, mostly lymph node 
metastases. 
 
Despite the plethora of literature addressing the 
issue of lymphadenectomy in EC, the place of lymph 






The aim of our study was to provide further data 
regarding the following topics: 
  
a) the incidence of node metastases in the pelvic and 
paraaortic region in women with pathologically staged 
T1 and T2 (pT1, pT2) endometrial carcinoma,  
b) how they correlate with the depth of myometrial 
invasion and the tumor grade? 
c) has lymph node dissection any survival benefit? 
d) evaluation of the occurrence and severity of 
intraoperative and postoperative complications    
 
PATIENTS AND METHODS 
 
We studied 272 histologically confirmed endometrial 
adenocarcinoma patients referred to the St. Stephen’s 
Hospital, Department of Gynecologic Oncology between 
01.01.1998 and 31.12.2005. Tumors with clear-cell and 
seropapillary histology were excludeed. Total 
abdominal hysterectomy and bilateral salpingo-
oophorectomy (TAH-BSO) with lymphadenectomy were 
performed in 143 instances (125 pelvic 
lymphadenectomy, 18 pelvic and paraaortic 
lymphadenectomy). Patients with lymph node sampling 
were excluded.  
Pelvic lymphadenectomy consisted of dissection of the 
external and common iliac as well as of the obturator 
nodes, whereas the paraaortic node dissection 
included removal of the pericaval and periaortic 
nodes up to the mesenteric inferior artery.  
 
We grouped our cased based on the TNM system by 
studying the removed uterus and adnexa 
histologically, i.e. determining the pathologic 
stage. Accordingly, pT1 was defined as tumor confined 
to the uterine fundus, and pT2 included those cases 
with involvement of the cervix; either the cervical 
mucosa only (pT2a) or the stoma with or without 
mucosal infiltration by the tumor cells (pT2b).   
 
Recently FIGO modified the staging system of the 
uterine cancer by separating the stage one disease in 
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two categories only: stage IA includes all 
endometrial cancer not infiltrating the myometrium 
more than 50%; whereas tumors with myometrial 
invasion of the outer half of the uterus are grouped 
as stage IB. 
 
Most of our patients (227) had pathologic pTI and 
pTII adenocarcinoma of the endometrium, and in the 
current paper we report the data of these 227 women.  
 
Mortality data were collected from the National 
Cancer Registry and the Central Office of Statistics. 
Other relevant data were collected from the hospital 
charts. The follow-up period was closed on 
01.06.2010. The correlation between the stages/grade 
and the risk of lymph node metastasis was evaluated 
by logistic regression analysis and estimating the 
Wilson confidence intervals (R programe [R 
Development Core Team (2009). http://www.R-
project.org.), a survival modul (2009). R package 
version 2.35-8. http://CRAN.R-
project.org/package=survival) and NCStats modul 
(Ogle, D.H. 2010. NCStats: Helper Functions for 
Statistics at Northland College. R package version 
0.2-1.). 
The 5-year survival and survival trends was evaluated 
by the follow-up data using Kaplan-Meier analysis.  
   
RESULTS 
 
Table 1 shows the stage distribution of 227 patients 
with with pT1 and 2 adenocarcinoma of the 
endometrium. Of them 194 (85.7%) had pathologic pT1 
and 33 (14.3%) had pT2 disease.  The mean age of the 
patients was 62.3 years. 
 
Ten (5.5%) of 194 patients with pT1 uterine cancer 
who underwent lymphadenectomy had positive pelvic 
nodes and in 4 (2%) of these ten women the paraaortic 
nodes harbored metastatic disease. 44.4 % of women 
with pT1 tumor and positive pelvic nodes had 
paraaortic secondary. None of the patients had 
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positive paraaortic node metastasis without pelvic 
node involvement. The 5-year survival was 63%. In 
this group 34 patients died from cancer recurrence or 
disseminated tumor.  
 
The pelvic nodes were positive in 3 cases (11.1%) out 
of 27 women with pT2 adenocarcinoma subjected to 
lymphadenectomy. Two of them had positive paraaortic 
nodes as well. Two other women had positive 
paraaortic nodes alone, i.e. their pelvic nodes were 
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Table 1. Distribution of grade and lymph node involvement in 
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Table 2: Risk of positive lymph nodes (CI:95%) 
 
 
DISTRIBUTION BASED ON SUBCATEGORIES 
 
a) pT1a 
None of the 22 patients with pT1a carcinoma had G3 
tumor, and in 68% of them the tumor was well 
differentiated (G1). Of the 22 women with pT1a 
adenocarcinoma, pelvic and paraaortic lymphadenectomy 
was performed in 8, all with negative nodes.  
The 5-year survival was 86% (78% - with LND; 88% - 
without LND).  
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b) pT1b  
135 women had tumor with less than 50% of endometrial 
invasion (pT1b), with 35.2% had G1, 44.6% G2 and 
20.1% G3 tumors. Of whom, 88 underwent pelvic and 
paraaortic lymph node dissection. One patient (3.8%) 
with G1, two (4,7%) with G2 and 5 (22,7%) with G3 
disease had positive pelvic nodes. In the G3 group 
the paraaortic nodes were positive in 4 (19). None of 
women with pT1b and G1 or G2 uterine cancer had 
positive paraaortic nodes. The rate of 5 year 
survival was 62% (84 patients). 
 
c) pT1a + pT1b (157 patients) 
In this group the 5 year survival rate was 65%.  
 
d) pT1c 
Thirty seven patients of 194 women with stage I tumor 
had pTIc adenocarcinoma. Of them G1 tumor occurred in 
9 (24.3%), G2 (56,7) in 21 and G3 in 7 (18.9%) 
patients. Pelvic and paraaortic nodes were dissected 
in 4 of G1, 9 in G2 and 7 in G3 cases. None of the 
patients with G1 disease had positive nodes. One 
woman (11,1%) with pTIc G2 tumor had positive pelvic 
nodes without paraartic nodal involvement, and one of 
seven patients (14,3%) with undifferentiated (G3) 
adenocarcinoma was found to carry pelvic and 
paraaortic secondary. The 5 year survival rate was 
54%.        
  
e) pT2a 
Ten women of 33 with pT2 disease had pT2a tumor (G1 
1, G2 6 and G3 3), and 9 had pelvic and paraaortic 
node dissection. None had positive nodes with 80% 5 
year survival rate.      
 
f) pT2b 
Twenty three of 23 patients with pTII disease had 
pTIIb tumor (G1 3, G2 12 and G3 8). Of them 18 had 
pelvic and paraaortic node dissection. The pelvic 
nodes were positive in 5 cases (27.7%) out of 18 
women with pT2 adenocarcinoma subjected to 
lymphadenectomy. Two of them had positive paraaortic 
nodes as well, and another two had positive 
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paraaortic nodes alone, with negative pelvic nodes. 
The 5 year survival rate was 21.7%.   
 
Abbreviations: LND=lymph node dissection; LN=lymph node 
 
 n (cases) <5 year >5 year 
Overall 22 3 19 (86%) 
without LND 14 3 11 (78.57%) 
with LND 8 1 7 (87.5%) 
Table 3: Survival of pT1a cases 
  
 
 n <5 year  >5 year 
Overall 135 51 84(62%) 
without LND 47 18 31 (65.95%) 
with LND 88 23 53 (60.2%) 
Positive 
pelvic LN 
8 8 0 
Positive PAO 
LN 
2 2 0 
Table 4: Survival of pT1b cases  
 
 n <5 year >5 year 
Overall 37 17 20 (54%) 
without LND 17 8 9 (52.9%) 
with LND 20 9 11 (55%) 
Positive LN 2 1 1  
Positive PAO 
LN 
1 1 0  
Table 5: Survival of pT1c cases  
 
 n <5 years >5 years 
 10 2 8 (80%) 
without LND 1 1 0 
with LND 9 2 7 (77.7%) 
Positive LN 0   
Table 6: Survival of pT2a cases  
 
 
 n <5 years >5 years 
 23 18 5 (21.7%) 
without LND 5 4 1 (20%) 
with LND 18 13 5 (27.7%) 
Positive LN 5 4 1  
Positive PAO 
LN 
2 2 0 
Table 7: Survival of pT2b cases  
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NODAL INVOLVEMENT IN pT1 CASES ACCORDING TO THE TUMOR 
DIFFERENTIATION (Tables 8-10) 
 
a) Well differentiated (G1) adenocarcinomas 
Lymphadenectomy was performed in 34 patients, and 
there was only a single case of positive pelvic 
nodes, and no paraaortic involvement.  
 
b) G2 adenocarcinomas 
Fifty four of them underwent lymph node dissection (3 
pelvic and PAO LND). Three (3.37%) had positive 
pelvic nodes. There was no paraaortic metastasis.     
 
c) G3 adenocarcinomas 
Lymphadenectomy was performed in 28 cases. Six had 
positive pelvic (21,4%) and 5 of them positive 
paraaortic nodes (13,8%).  
 
 OR 2,5% CI 97.5% CI 
pT1a 0.00 - - 
pT1b 1.00 1.00 1.00 
pT1c 0.88 0.12 4.14 
pT2a 0.00 - - 
pT2b 3.50 0.88 13.39 
G1 0.39 0.02 2.06 
G2 1.00 1.00 1.00 
G3 4.07 1.24 15 
Table 8: Odds ratios of positive pelvic lymph nodes (Reference 
group: pT1b, G2; OR: odds ratio, CI: confidence interval) 
 
 pT1a pT1b pT1c pT2a pT2b 
G1 0 4% 0 0 0 
G2 0 5% 11% 0 22% 
G3 0 24% 14% 0 50% 
 
Table 9: Patients with positive LNs (%) according pathological 
stage and grade 
 
 pT1a pT1b pT1c pT2a pT2b 
G1 5 24 4 1 3 
G2 3 40 8 5 7 
G3 0 16 6 3 3 
 
Table 10: Patients with negative LN-s (%) according 


















Figure 1: Overall survival in months (n:227) 
 
 














Figure 2: Overall survival (n:227; positive pelvic 


















Figure 3: Disease-free survival (n:227; CI:95%) 
 
 














Figure 4: Disease-free survival (positive pelvic 












There were no serious bladder, bowel or vascular 
injuries associated with surgeries.  
Lymphocyst and mild lymphedema occurred in 1 patient 
but this was cured conservatively. Two patients died 




Due to the limitations of clinical assessment of EC, 
FIGO switched to clinical staging to surgical one in 
1988. However, guidelines for assessing lymph node 
status was not provided, consequently controversy is 
still exists in terms of indication and extent of 
lymphadenectomy, particularly in women with early-
stage EC. In spite of the GOG recommendations the 
indication and the anatomic extent of lymph node 
dissection have yet to be defined. No doubt, removing 
negative nodes has no benefit, but rather harmful due 
to its minor adverse effect on the immune system and 
potential complications. With this in mind, 
lymphadenectomy is indicated when there is a 
substantial risk of lymph node involvement only. 
Nodal dissection for staging sake alone may raise 
ethical issue. Our results in agreement with the 
literature data show that nodal involvement in women 
with endometrial adenocarcinoma confined to the 
uterine fundus is less than 10% in total, and that 
nodal involvement is most common in poorly 
differentiated (G3) tumors.  Our data support the 
view of FIGO that pT2a is not a separate prognostic 
group. On the contrary, we found that in patients 
with pT1 G3 tumors the nodal involvement is 
substantial even when the myometrial invasion is less 
than 50% (pT1b).   Of interest, paraaortic nodes were 
positive only in G3 cases, always in the presence of 
pelvic node metastasis. In more than 50% of pelvic 
node positive women with pTI G3 tumors the paraaortic 
nodes were also involved. One may conclude the there 
is a place for pelvic node dissection pT1 G3 cases in 
the presence of myometrial invasion, irrespective of 
the depth of invasion. Once the pelvic nodes turn out 
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to be positive in frozen section, paraartic node 
dissection is indicated. Unfortunately, our data do 
not permit draw any conclusion in this context when 
the tumor is confined to the endometrium only, i.e. 
when there is no myometrial involvement. Unlike 
cervical carcinoma, in endometrial cancer the common 
iliac and particularly the periaortic nodes are not 
affected on secondary or progressive bases. Our data 
are in line with this concept in pT2b cases only, 
i.e. when the tumor invades the cervical stroma. 
However, the number of patients is small to draw 
final conclusions in this setting.  As a substantial 
positive nodes are situated above the IMA, para-
aortic node dissection is deemed to be extended up to 
the renal vessels. With para-aortic node dissection 
up to the IMA, 40-45% of positive para-aortic nodes 
would be missed. Postoperative pelvic radiotherapy 
with or without intravaginal irradiation would 
undertreat many women with high-risk EC because of 
the high incidence of para-aortic nodal involvement, 





1. In case of endometrial adenocarcinoma confined to 
the uterine corpus, if certain risk factors are 
present pelvic and para-aortic lymph node 
dissection is indicated. Lymph node dissection 
provides prognostic informations and is part of 
surgical staging. Since ~60% of the lymph node 
metastases are located in the pelvic, ~40% in the 
para-aortic area, approximately half of patients 
with positive pelvic nodes has positive para-
aortic nodes  and because in ~15% only the para-
aortic nodes are involved, both pelvic and para-
aortic node dissection is recommended in patients 
with high-risk EC, who are considered for lymph 
node evaluation. 
2. Although the grade and myometrial infiltration 
are independent risk factors affecting lymph node 
involvement, it is recommended to stratify 




3. According to our data we agree that in case of G1 
and G2 tumors pelvic lymphadenectomy might be 
omitted, but this decision has to be based on the 
result of intraoperative histology.  
4. If the intaroperative pathological examination 
reveals negative pelvic lymph nodes, the 
omittance of para-aortic dissection can be 
considered  
5. In pT2 carcinomas (cervical stromal infiltration) 
pelvic and paraaortic lymphadenectomy is 
indicated. 
6. In our study in the group of pT2 endometrial 
adencoracinomas the causes of death were distant 
metastasis. Due to this fact radical hysterectomy 
is not indicated because adjuvant irradiation can 
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